GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4

Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese

The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects

Lead sponsor

Universiti Kebangsaan Malaysia Medical Centre

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Feeding And Eating Disorders, Obesity / overweight

Key I/E criterion

•BMI 30-45

Primary endpoint

•Binge eating scale score

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01739049

Org study IDFF0192012

Timeline

Milestones

Study first posted2012-11-30estimated

Last update posted2017-05-04actual

Study start2012-11 (month precision)

Primary completion2013-10actual (month precision)

Study completion2015-01actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Feeding And Eating DisordersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Subjects who are willing to participate and sign informed consent form

•Subjects who are able to answer the questionnaire

•Subjects who are between 18-65 years old

•Subjects with BMI 30-45

•Subjects who are willing to administer injection

Exclusion criteria

•Pregnant subjects

•Subjects with chronic medical illness such as end stage renal failure, hepatic failure, diabetes mellitus, thyroidism, etc

•Subjects on medication that may influence appetite, satiety and weight

•Subjects that plan to move out of state/country

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Other clinical outcomes

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Reduction in weight

Time frame:12 weeks

change from baseline, improvement

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

Reduction in binge eating scale score

Time frame:12 weeks

change from baseline, improvement

Other (unclassified)

1 endpoint

Other/protocol endpoint/low confidence

Profile of hormones

Time frame:12 weeks

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.
Obesity research & clinical practice2015 May-Jun (year)PMID25870084doi:10.1016/j.orcp.2015.03.005via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.